Cornea · 2026
Cultured Human Corneal Endothelial Cell Injection (Vyznova) in Eyes with Extremely Low Intraocular Pressure After Glaucoma Surgery: Case Reports.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ogino Rintaro, Shirane Mariko, Ibrahim Osama, Yagi-Yaguchi Yukari, Tomida Daisuke, Yamaguchi Takefumi
Аннотация
PURPOSE: Eyes with extremely low intraocular pressure (IOP) less than 4 mm Hg after glaucoma surgery represent a major challenge for endothelial keratoplasty, as inadequate anterior chamber support often leads to graft detachment and early graft failure. Cultivated human corneal endothelial cell (cHCEC) injection has recently emerged as a graft-free therapeutic alternative; however, its efficacy in eyes with extremely low IOP has not been well established.
METHODS: This case series describes the clinical outcomes of cHCEC therapy using Vyznova in 2 patients with bullous keratopathy (BK) and preoperative IOP of ≤4 mm Hg after prior filtering glaucoma procedures.
RESULTS: In case 1, corneal edema resolved rapidly after cHCEC injection, with improvement in best-corrected visual acuity (BCVA) from 20/2000 to 20/30 at 1 month and 20/25 at 3 months. Central corneal thickness (CCT) decreased from 747 μm preoperatively to 517 μm at 3 months. Endothelial cell density (ECD) reached approximately 2600 cells/mm 2 at 1 month and was maintained at 3 months. In case 2, corneal clarity was restored early after surgery, and BCVA improved from 20/400 to 20/20 at 1 month, remaining stable at 3 months. CCT decreased from 859 μm to 535 μm. ECD was approximately 1500 cells/mm 2 at 1 month and remained stable at 3 months. IOP remained low throughout follow-up in both cases.
CONCLUSIONS: These cases highlight that cHCEC therapy may be a safe and effective treatment for BK in eyes with extremely low IOP after glaucoma surgery, representing a promising alternative when conventional endothelial keratoplasty carries a high risk.
METHODS: This case series describes the clinical outcomes of cHCEC therapy using Vyznova in 2 patients with bullous keratopathy (BK) and preoperative IOP of ≤4 mm Hg after prior filtering glaucoma procedures.
RESULTS: In case 1, corneal edema resolved rapidly after cHCEC injection, with improvement in best-corrected visual acuity (BCVA) from 20/2000 to 20/30 at 1 month and 20/25 at 3 months. Central corneal thickness (CCT) decreased from 747 μm preoperatively to 517 μm at 3 months. Endothelial cell density (ECD) reached approximately 2600 cells/mm 2 at 1 month and was maintained at 3 months. In case 2, corneal clarity was restored early after surgery, and BCVA improved from 20/400 to 20/20 at 1 month, remaining stable at 3 months. CCT decreased from 859 μm to 535 μm. ECD was approximately 1500 cells/mm 2 at 1 month and remained stable at 3 months. IOP remained low throughout follow-up in both cases.
CONCLUSIONS: These cases highlight that cHCEC therapy may be a safe and effective treatment for BK in eyes with extremely low IOP after glaucoma surgery, representing a promising alternative when conventional endothelial keratoplasty carries a high risk.